ArticleJACC. Asia2026
Oncologic Benefits and Cardiovascular Risks of Pembrolizumab: Insights From a Nationwide Lung Adenocarcinoma Cohort.
Chan Soon Park et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it